Palisade Bio Leadership Executes Strategic Stock Transactions Amid Clinical Milestones
Palisade Bio, Inc. (NASDAQ: PALI) has seen significant insider activity as Chief Executive Officer and Chief Financial Officer John David Finley executed a substantial sale of company shares. The transaction, valued at approximately $303,343, was primarily driven by the need to cover tax withholding obligations related to the vesting of restricted …